Please login to the form below

Not currently logged in
Email:
Password:

Perjeta

This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.

Ocrevus surge keeps Roche smiling in Q3

Ocrevus surge keeps Roche smiling in Q3

However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led

Latest news

More from news
Approximately 17 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics